MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.410
-0.010 (-0.70%)
At close: Apr 22, 2026, 4:00 PM EDT
1.430
+0.020 (1.42%)
After-hours: Apr 22, 2026, 4:26 PM EDT
MediciNova Revenue
In the year 2025, MediciNova had annual revenue of $409.66K. MediciNova had revenue of $151.74K in the quarter ending December 31, 2025.
Revenue (ttm)
$409.66K
Revenue Growth
n/a
P/S Ratio
169.41
Revenue / Employee
$68,276
Employees
6
Market Cap
69.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 409.66K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 4.04M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 6.00M | 5.20M | 648.00% |
| Dec 31, 2012 | 802.58K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | 263.88K | -540.19K | -67.18% |
| Dec 31, 2005 | 804.07K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 63.26M |
| ImmuCell | 27.64M |
| Cue Biopharma | 27.47M |
| BeyondSpring | 1.88M |
| Spruce Biosciences | 697.00K |
| iBio, Inc. | 300.00K |
MNOV News
- 5 weeks ago - MediciNova to Participate at the 38th Annual ROTH Conference - GlobeNewsWire
- 2 months ago - MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients - GlobeNewsWire
- 3 months ago - 2026 New Year's Greetings from the CEO - GlobeNewsWire
- 4 months ago - MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy - GlobeNewsWire
- 4 months ago - MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND - GlobeNewsWire
- 5 months ago - MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor - GlobeNewsWire
- 5 months ago - MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards - GlobeNewsWire
- 6 months ago - MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication - GlobeNewsWire